Future Perspectives and Unmet Needs for Patients With MDS
Jamie L. Koprivnikar, MD, closes by sharing some future insights and remaining unmet needs for patients with myelodysplastic syndrome.
Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS
Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.
Efficacy and Safety of Luspatercept in MDS: Key Data from the COMMANDS Trial
A review of the rationale and study design of the phase 3 COMMANDS trial and subsequent subgroup analysis data recently presented at the ASCO and EHA 2023 Annual Meetings.
Luspatercept as a Treatment Option in MDS
Jamie L. Koprivnikar, MD, reviews luspatercept as a treatment option in myelodysplastic syndrome and the adverse events most frequently seen with her patients in clinical practice.
Current Unmet Needs for Patients With Low-Risk MDS in the Frontline Setting
Dr Jamie L. Koprivnikar comments on the currently unmet needs for patients with low-risk myelodysplastic syndrome in the front-line setting.
Differences in Treatment Approaches for Low-Risk and High-Risk MDS
Jamie L. Koprivnikar, MD, details how her treatment approaches differ for patients with low-risk versus high-risk myelodysplastic syndrome.
Approaches to Diagnosis and Risk Assessment for Patients With MDS
Dr Jamie L. Koprivnikar describes her general approaches to diagnosing and risk stratifying patients with myelodysplastic syndrome, and how she differentiates high-risk and low-risk disease.
Case Presentation: A 72-Year-Old Woman with Single Lineage Dysplasia Myelodysplastic Syndrome (MDS)
Jamie L. Koprivnikar, MD, presents the case of a 72-year-old woman diagnosed with single lineage dysplasia myelodysplastic syndrome and shares her initial impressions.
2 Clarke Drive Cranbury, NJ 08512